Edition:
United States

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

3.28USD
26 May 2017
Change (% chg)

$-0.17 (-4.93%)
Prev Close
$3.45
Open
$3.45
Day's High
$3.50
Day's Low
$3.28
Volume
61,014
Avg. Vol
67,866
52-wk High
$5.67
52-wk Low
$1.48

Latest Key Developments (Source: Significant Developments)

Fate Therapeutics reports Q1 loss per share of $0.24
Monday, 15 May 2017 04:01pm EDT 

May 15 (Reuters) - Fate Therapeutics Inc :Reports first quarter 2017 financial results.Q1 revenue $1.0 million versus I/B/E/S view $947,000.Qtrly net loss per common share, basic and diluted $0.24.Research and development expenses were $8.0 million for Q1 of 2017 compared to $6.6 million for comparable period in 2016.  Full Article

Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Fate Therapeutics Inc :Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100 in advanced solid tumors.  Full Article

Fate Therapeutics qtrly net loss per common share $ 0.21
Thursday, 16 Mar 2017 04:01pm EDT 

Fate Therapeutics Inc : Fate Therapeutics reports fourth quarter 2016 financial results . Q4 revenue $1.0 million versus I/B/E/S view $958,000 . Qtrly net loss per common share $ 0.21 . Fate Therapeutics Inc - cash, cash equivalents and short-term investments as of dec 31, 2016 were $92.1 million compared to $64.8 million as of dec 31, 2015 .Q4 earnings per share view $-0.29, revenue view $957500.00 -- Thomson Reuters I/B/E/S.  Full Article

Fate Therapeutics says investigational new drug application for its cancer drug gets FDA clearance
Monday, 13 Mar 2017 08:00am EDT 

Fate Therapeutics Inc - : Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100 natural killer cell cancer immunotherapy .Fate Therapeutics -expects a first-in-human clinical trial of fate-nk100 for aml to open enrollment at masonic cancer center, university of Minnesota.  Full Article

Fate Therapeutics files to say resale of up to 20.9 mln shares of common
Wednesday, 25 Jan 2017 05:07pm EST 

Fate Therapeutics Inc :Fate Therapeutics - files to say resale of up to 20.9 million shares of common stock by the selling stockholders named.  Full Article

Fate Therapeutics raises $56.75 million in equity financing
Thursday, 8 Dec 2016 06:20am EST 

Fate Therapeutics Inc - : Says it has raised $56.75 million in equity financing - SEC filing .Fate Therapeutics Inc disclosed in form D with U.S. SEC that total offering amount was for $56.75 million.  Full Article

Fate Therapeutics reports Q3 2016 financial results
Monday, 7 Nov 2016 04:01pm EST 

Fate Therapeutics Inc : Fate Therapeutics reports third quarter 2016 financial results .Q3 revenue $1.0 million versus I/B/E/S view $951,000.  Full Article

Fate Therapeutics reports Q2 2016 financial results
Monday, 8 Aug 2016 04:01pm EDT 

Fate Therapeutics Inc : Fate Therapeutics reports second quarter 2016 financial results . Q2 revenue $1.0 million versus I/B/E/S view $866,000 . Says Ind Filing For Allogeneic Memory Like NK cell cancer immunotherapy planned for 2016 .Qtrly loss per share $0.29.  Full Article

Fate Therapeutics says $10.3 million common stock private placement
Monday, 8 Aug 2016 08:00am EDT 

Fate Therapeutics Inc: Fate Therapeutics announces $10.3 million common stock private placement . Investors have agreed to purchase 5.3 million shares of company's common stock at a price of $1.96 per share .Expects to use proceeds from transaction primarily to advance its pipeline of programmed cellular immunotherapies among others.  Full Article

Fate Therapeutics announces FDA fast track designation for Protmune
Monday, 20 Jun 2016 08:01am EDT 

Fate Therapeutics Inc : Says FDA has granted fast track designation for Protmune .Fate Therapeutics announces FDA fast track designation for Protmune.  Full Article

More From Around the Web

BRIEF-Fate Therapeutics reports Q1 loss per share of $0.24

* Research and development expenses were $8.0 million for Q1 of 2017 compared to $6.6 million for comparable period in 2016 Source text for Eikon: Further company coverage: